Satisfying needs for

niche Specialty Care products

 
00 / pharma& news

19/04/2021

pharma& is happy to announce that a share purchase agreement with Zatortia Holdings Ltd., Limassol, Cyprus (subsidiary of Shilpa Medicare Ltd., India) has been entered to acquire 100% of shares of LOBA Feinchemie GmbH, Fischamend, Austria.

This acquisition enables pharma& to vertically integrate a high-quality Active Pharmaceuticals Ingredient producer in order to secure long-term supply of its highly niche specialty care medicines. LOBA renews its firm commitment to the development and production of  high quality Intermediates, Fine Chemicals and Active Pharmaceutical Ingredients and is looking forward to build upon the trusted and long-lasting customer relationships having been established in the past.

more news /

01 / pharma& is

pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.

Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.

02 / pharma& story

After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.

We are proud of our “every patient counts” commitment and our strong partnership network.

03 / pharma& team

All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.

 

Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.

04 / pharma& founders
 
 

Frank Rotmann

  • Grey LinkedIn Icon

" Throughout my 20+ years

in the industry, I have developed a track record in building

and developing organisations

for growth! "

Elmar Zagler

  • Grey LinkedIn Icon

" Having started my career in Finance, I know how to optimize businesses and

how to leverage

networks & alliances! "

05 / pharma& portfolio
05.1 / prescription medicines
05.2 / consumer health
05.3 / affiliated companies
 

06 / pharma& pharmacovigilance contact

IN GERMAN

Bei Nebenwirkungen wenden Sie sich bitte an

oder schreiben Sie ein Email an pv@drehm.at.  

Zusätzlich können Sie auch direkt über die Homepage des Bundesamtes für Sicherheit im Gesundheitswesen (http://www.basg.gv.at) Nebenwirkungsfälle melden.

IN ENGLISH

In case of adverse events, please contact

or send an Email to pv@drehm.at.  

Additionally, you can also report adverse events via your local health authorities.

IN DUTCH

Voor het melden van bijwerkingen, contacteer

of u kunt een e-mail sturen naar pharmacovigilance@bfc.nl.

Daarnaast kunt u bijwerkingen ook melden bij het Lareb, www.lareb.nl.